The purpose of the study is to collect information on how Xultophy® works in patients with type 2 diabetes. The participants will get Xultophy® as prescribed to them by the study doctor. The study will last for about 26-34 weeks. The participants will be asked questions about their health and their diabetes treatment as part of their normal study doctor's appointment.
Study Type
OBSERVATIONAL
Enrollment
300
Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.
Novo Nordisk Investigational Site
Abu Dhabi, United Arab Emirates
Novo Nordisk Investigational Site
Ajman, United Arab Emirates
Novo Nordisk Investigational Site
Dubai, United Arab Emirates
Change in laboratory measured glycosylated haemoglobin A1c (HbA1c)
Measured in % point
Time frame: From baseline [≤12 weeks prior to treatment initiation [week 0]) to end of study (26-34 weeks)
Patients reached HbA1c less than 7% at end of study (Yes/No )
Number of patients who achieved/not achieved HbA1c at end of study: \<7.0%
Time frame: At the end of study visit (26-34 weeks)
Change in laboratory measured fasting plasma glucose (FPG)
Measured in mg/dL
Time frame: From baseline [≤12 weeks prior to treatment initiation [week 0]) to end of study (26-34 weeks)
Average dose step of Xultophy® at end of the study
Measured in dose steps/day
Time frame: At the end of study (26-34 weeks)
Change of body weight
Measured in kg
Time frame: From baseline [≤12 weeks prior to treatment initiation [week 0]) to end of study (26-34 weeks)
Change in number of patient self-reported overall non-severe hypoglycaemic episodes based on recollection
Number of episodes
Time frame: Pre- to post- initiation of treatment with Xultophy®. Episodes occurring within 4 weeks prior to initiation of treatment with Xultophy® and to within 4 weeks prior to end of study (26-34 weeks)
Change in number of patient self-reported nocturnal non-severe hypoglycaemic episodes based on recollection
Number of episodes
Time frame: Pre- to post- initiation of treatment with Xultophy®. Episodes occurring within 4 weeks prior to initiation of treatment with Xultophy® and to within 4 weeks prior to end of study (26-34 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in number of patient self-reported severe hypoglycaemic episodes based on recollection (overall)
Number of episodes
Time frame: Pre- to post- initiation of treatment with Xultophy®. Episodes occurring within 26 weeks prior to initiation of treatment with Xultophy® and to within 26 weeks prior to end of study (26-34 weeks)
Reason(s) for discontinuing treatment with Xultophy® during the treatment period, if applicable
Pre-specified response option(s)
Time frame: At the end of study (26-34 weeks)